NeuroPace (NASDAQ:NPCE) Cut to “Equal Weight” at Wells Fargo & Company

NeuroPace (NASDAQ:NPCE) was downgraded by research analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research report issued on Friday, Briefing.com reports. They currently have a $9.00 target price on the stock. Wells Fargo & Company‘s price objective indicates a potential downside of 25.12% from the stock’s current price.

Several other research firms have also commented on NPCE. Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Cantor Fitzgerald restated an “overweight” rating on shares of NeuroPace in a research note on Tuesday, September 15th. Mizuho assumed coverage on NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of NeuroPace in a report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. downgraded NeuroPace from an “overweight” rating to a “neutral” rating and set a $9.00 price target for the company. in a research report on Friday. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, NeuroPace currently has a consensus rating of “Hold” and a consensus price target of $15.50.

NeuroPace Stock Performance

Shares of NPCE stock opened at $12.02 on Friday. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. The firm has a 50-day moving average of $13.35 and a 200-day moving average of $14.79. NeuroPace has a one year low of $11.90 and a one year high of $19.60. The company has a market cap of $412.53 million, a P/E ratio of -21.09 and a beta of 1.98.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. The business had revenue of $22.83 million for the quarter, compared to analysts’ expectations of $22.61 million. Equities research analysts forecast that NeuroPace will post -0.67 EPS for the current fiscal year.

Hedge Funds Weigh In On NeuroPace

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in NeuroPace during the second quarter valued at about $39,369,000. First Light Asset Management LLC raised its position in NeuroPace by 82.3% in the first quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock worth $32,349,000 after acquiring an additional 1,110,484 shares during the period. Deutsche Bank AG bought a new stake in NeuroPace in the second quarter worth about $14,919,000. GSA Capital Partners LLP bought a new stake in NeuroPace in the second quarter worth about $1,836,000. Finally, Man Group plc purchased a new position in NeuroPace in the second quarter valued at about $1,336,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about NeuroPace

These are some of the NPCE headlines that stood out recently:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

NeuroPace Company Profile

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.